文献速递间质性肺疾病

家族性肺纤维化:遗传特征与临床意义

Familial Pulmonary Fibrosis: Genetic Features and Clinical Implications.
PubMed 文献 · Chest · 2021-06-26

家族性肺纤维化(FPF)指至少一名亲属同样患病的肺纤维化亚群,表型多样但以特发性肺纤维化最常见,生存劣于散发病例。已发现表面活性物质代谢和端粒维持基因的罕见变异,但仅解释约四分之一FPF家系,需继续寻找缺失的遗传因素。

要点

  • 阳性家族史提示预后更差,并应怀疑致病遗传变异。
  • 表面活性物质与端粒相关基因罕见变异可见于FPF及散发病例。
  • 罕见变异可辅助评估未患病亲属风险及患者预后与治疗策略。

核心结论

  • FPF患者生存较散发性肺纤维化患者更差。
  • 表面活性物质和端粒相关基因罕见变异仅解释约四分之一FPF家系的遗传基础。

研究设计与样本

  • 本文为综述,聚焦家族性肺纤维化家系的遗传特征与临床意义。

主要发现

  • FPF患者呈现广泛的肺纤维化表型,以特发性肺纤维化最常见。
  • 已发现表面活性物质代谢和端粒维持基因的罕见变异与FPF相关。
  • 类似罕见变异也见于看似散发性肺纤维化患者,支持遗传易感性普遍存在。

关键数值与推荐

  • FPF定义为至少一名其他亲属同样患病的肺纤维化患者。
  • 罕见变异仅解释约四分之一FPF家系的遗传基础。

临床怎么用

  • 询问家族史可提供预后信息,并应怀疑家系内遗传变异。
  • 罕见变异信息可用于评估未患病亲属的易感风险。
  • 罕见变异信息可辅助已患病者的预后判断和治疗策略。

局限性

  • 表面活性物质和端粒相关基因罕见变异仅解释约四分之一FPF家系,缺失遗传因素尚待研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pulmonary fibrosis comprises a wide range of fibrotic lung diseases with unknown pathogenesis and poor prognosis. Familial pulmonary fibrosis (FPF) represents a unique subgroup of patients in which at least one other relative is also affected. Patients with FPF exhibit a wide range of pulmonary fibrosis phenotypes, although idiopathic pulmonary fibrosis is the most common subtype. Despite variable disease manifestations, patients with FPF experience worse survival compared with their counterparts with the sporadic disease form. Therefore, ascertaining a positive family history not only provides prognostic value but should also raise suspicion for the inheritance of an underlying causative genetic variant within kindreds. By focusing on FPF kindreds, rare variants within surfactant metabolism and telomere maintenance genes have been discovered. However, such genetic variation is not solely restricted to FPF, as similar rare variants are found in patients with seemingly sporadic pulmonary fibrosis, further supporting the idea of genetic susceptibility underlying pulmonary fibrosis as a whole. Researchers are beginning to show how the presence of rare variants may inform clinical management, such as informing predisposition risk for yet unaffected relatives as well as informing prognosis and therapeutic strategy for those already affected. Despite these advances, rare variants in surfactant and telomere-related genes only explain the genetic basis in about one-quarter of FPF kindreds. Therefore, research is needed to identify the missing genetic contributors of pulmonary fibrosis, which would not only improve our understanding of disease pathobiology but may offer additional opportunities to improve the health of patients.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Zhang D, Newton CA. Familial Pulmonary Fibrosis: Genetic Features and Clinical Implications. Chest. 2021. PMID: 34186035. doi:10.1016/j.chest.2021.06.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。